Tehran University of Medical Sciences

Science Communicator Platform

Share By
177Lu-Labeled Cyclic Rgd Peptide As an Imaging and Targeted Radionuclide Therapeutic Agent in Non-Small Cell Lung Cancer: Biological Evaluation and Preclinical Study Publisher Pubmed



Pirooznia N1 ; Abdi K1 ; Beiki D2 ; Emami F3 ; Arab SS4 ; Sabzevari O5 ; Soltanigooshkhaneh S3
Authors

Source: Bioorganic Chemistry Published:2020


Abstract

Non-small cell lung carcinoma (NSCLC) is among the most lethal lung cancers responsible for 80–85% of death. αvβ3 integrin receptor subtype has been identified as a lung cancer biomarker since its expression correlates with tumor progression and metastasis. The extracellular domain of the receptor forms a binding site for RGD-based sequences. Therefore, specific targeting of αvβ3 integrin receptors by these short peptides can be an excellent candidate for cancer imaging and therapy. In this research, the radiolabeling of DOTA-E(cRGDfK)2 with 177Lu was efficiently implemented. The Log P value, in vivo, in vitro, metabolic stability, cellular uptake and specific binding of the radiopeptide was determined. The tumor targeting capacity and the therapeutic potential of the radiotracer was studied in A549 tumor-bearing mice. Imaging studies at different time intervals were performed by SPECT/CT. Radiochemical purity of more than 99% and Log P of −3.878 was obtained for 177Lu-labelled peptide. Radiotracer showed favorable in vivo, in vitro and metabolic stability. The radiopeptide dissociation constant (Kd) was 15.07 nM. Radiopeptide specific binding was more than 95%. Biodistribution studies showed high accumulation of the radiopeptide in tumor and rapid excretion by urinary route. Maximum tumor uptake was at 4 h post-injection. Following administration of this radiopeptide to mice, not only tumor growth was suppressed, but significant tumor shrinkage was also observed. In conclusion, this radiopeptide can be employed for staging, follow-up imaging and as peptide receptor radionuclide therapeutic agent allowing efficient therapy for NSCLC and other cancers overexpressing αvβ3 integrin receptors. © 2020 Elsevier Inc.
Related Docs
View other Related Docs
1. Radiosynthesis, Biological Evaluation, and Preclinical Study of a 68Ga-Labeled Cyclic Rgd Peptide As an Early Diagnostic Agent for Overexpressed Α V Β 3 Integrin Receptors in Non-Small-Cell Lung Cancer, Contrast Media and Molecular Imaging (2020)
2. Development of a 99Mtc-Labeled Cxcr4 Antagonist Derivative As a New Tumor Radiotracer, Cancer Biotherapy and Radiopharmaceuticals (2018)
3. 99Mtc Labeled Hynic-Edda/Tricine-Ge11 Peptide As a Successful Tumor Targeting Agent, Medicinal Chemistry Research (2018)
Experts (# of related papers)
View all Related Experts
Davood Beiki (7)
Omid Sabzevari (7)
Other Related Docs
4. Design, Preparation and Biological Evaluation of a 177Lu-Labeled Somatostatin Receptor Antagonist for Targeted Therapy of Neuroendocrine Tumors, Bioorganic Chemistry (2020)
5. Breast Tumor Targeting in Mice Bearing 4T1 Tumor With Labeled Cxcr4 Antagonist Analogue, International Journal of Peptide Research and Therapeutics (2021)
6. Synthesis and Evaluation of a 99Mtc-Labeled Chemokine Receptor Antagonist Peptide for Imaging of Chemokine Receptor Expressing Tumors, Nuclear Medicine and Biology (2017)
7. Development of a 99Mtc-Labeled Lactam Bridge-Cyclized Alpha-Msh Derivative Peptide As a Possible Single Photon Imaging Agent for Melanoma Tumors, Annals of Nuclear Medicine (2015)
8. Preparation and Preclinical Evaluation of a Gd(Ιιι)-Rgd Peptide for Mr Molecular Imaging in Non-Small Cell Lung Carcinoma (Nsclc), Iranian Journal of Nuclear Medicine (2023)
9. Synthesis and Preliminary Evaluation of a New 99Mtc Labeled Substance P Analogue As a Potential Tumor Imaging Agent, Iranian Journal of Pharmaceutical Research (2015)
10. New 99M Tc(Co) 3 -Radiolabeled Arylpiperazine Pharmacophore As Potent 5Ht 1A Serotonin Receptor Radiotracer: Docking Studies, Chemical Synthesis, Radiolabeling, and Biological Evaluation, Journal of Labelled Compounds and Radiopharmaceuticals (2019)
11. A99mtc-Tricine-Hynic-Labeled Peptide Targeting the Melanocortin-1 Receptor for Melanoma Imaging, Iranian Journal of Pharmaceutical Research (2016)
12. Application of Radiolabeled Peptides in Tumor Imaging and Therapy, Life Sciences (2020)
13. Design of a New 99M99mtc-Radiolabeled Cyclo-Peptide As Promising Molecular Imaging Agent of Cxcr4 Receptor: Molecular Docking, Synthesis, Radiolabeling, and Biological Evaluation, Current Radiopharmaceuticals (2024)
14. Targeting and Imaging of Her2 Overexpression Tumor With a New Peptide-Based 68Ga-Pet Radiotracer, Bioorganic Chemistry (2021)
15. Synthesis and Radiolabeling of Glu-Urea-Lys With 99Mtc-Tricarbonyl-Imidazole-Bathophenanthroline Disulfonate Chelation System and Biological Evaluation As Prostate-Specific Membrane Antigen Inhibitor, Cancer Biotherapy and Radiopharmaceuticals (2023)
16. Design, Synthesis, Radiolabeling and Biological Evaluation of New Urea-Based Peptides Targeting Prostate Specific Membrane Antigen, Bioorganic Chemistry (2020)